CVR 78881917Private limited company (ApS)Engroshandel med medicinalvarer og sygeplejeartikler (464610)København KFounded 1 Aug 1985
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about UNIPHARMA ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexGross profit
0
DKK, annual report 2024
Result
0
DKK, annual report 2024
Equity
-124K
DKK, annual report 2024
Ebba Dorrit Reumert100% of capital and votes
Ebba Dorrit Reumertuntil 3 Aug 2025
Ole Reumertuntil 3 Aug 2025
Owners of 5% or more. CVR registers shares in bands, not exact figures.
100% of capital and votessince 13 Jun 1997
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2024, DKK: Revenue not reported, Gross profit 0, Operating profit 0, Result for the year 0
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2024, DKK: Total assets 1, Equity -124K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -5 | Not reported | 0 | Not reported | Not reported |
| Gross profit | Not reported | Not reported | Not reported | 0 | 0 |
| Operating profit | -5 | 0 | 0 | 0 | 0 |
| Result for the year | -5 | -5 | 0 | 0 | 0 |
| Equity | 62 | 57 | 56 | -124 | -124 |
| Total assets | 180 | 180 | 181 | 0 | 0 |
| Employees (average) | Not reported | Not reported | Not reported | 0 | Not reported |
| Credit metrics (Dandex calculations) | |||||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for UNIPHARMA ApS:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCash, bonus issue from reservesPaid in 27,247 | None | 27,247 | None | 125,000 | |
| FoundingNot read from the announcement | None | None | None | 80,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Source: CVR, read 17 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 17 Nov 2026.
19 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Konkursdekret afsagt 16.04.2026 af Sø- og Handelsrettens Skifteretsafdeling
Likvidatorer:
Fratrådte:
Pernille Bigaard, den 16.04.2026.
Revision:
Likvidatorer:
Tiltrådte:
Sø- og Handelsrettens Skifteretsafdeling har udnævnt følgende likvidatorer: Pernille Bigaard, 1560 København V, den 05.02.2026.
Virksomheden tegnes af en likvidator
Virksomhedens kreditorer opfordres til at anmelde deres krav til likvidator. Krav skal anmeldes senest tre måneder fra dags dato.
Anmodning om opløsning, jf. selskabslovens § 225 sendt til Sø- og Handelsrettens Skifteretsafdeling den 15.01.2026
Direktion:
Fratrådte:
Adm. direktør Ebba Dorrit Reumert, (adm. dir), den 03.08.2025.
Direktion:
Fratrådte:
Ole Reumert, den 03.08.2025.
Ny adresse: Nygade 6, 1164 København K
Ny adresse: H.C. Andersens Boulevard 37, 4. tv, 1553 København V
Vedtægter ændret: 11.10.2017
Ny adresse: Nygade 4, 4., 1164 København K
Ny kommune: København
Revision:
Fratrådte:
BEIERHOLM, STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 13.06.2017.
Revision:
Fratrådte:
ERIK MUNK, STATSAUTORISERET REVISIONSAKTIESELSKAB, den 12.07.2016.
Tiltrådte:
CVR-NR. 32895468 BEIERHOLM, STATSAUTORISERET REVISIONSPARTNERSELSKAB, Ringstedvej 71, 4000 Roskilde, den 12.07.2016.
Direktion:
Udtrådt af direktionen:
Ebba Dorrit Reumert, den 22.05.2014.
Indtrådt i direktionen:
Direktør Peter Reumert (adm. dir), den 22.05.2014.
Direktion:
Udtrådt af direktionen:
Jørgen de Muzquiz Reumert, den 22.05.2014.
Indtrådt i direktionen:
Cand. Pharm Ebba Dorrit Reumert (adm. dir), den 22.05.2014.
Ny adresse:
Esperance Alle 6A, 2. tv., 2920 Charlottenlund.
Revision:
Udtrådt af revisionen:
Statsaut. revisor Erik Munk, den 20.04.2001.
Indtrådt i revisionen:
AP, STATSAUTORISEREDE REVISORER, 1007 København K, den 20.04.2001.
Vedtægter ændret:
24.02.1997.
Kapitalforhøjelse kr. 45.000,00: kr. 27.247,00 indbetalt kontant, kurs 100,00, kr. 17.753,00 indbetalt ved overførte reserver / overskud, kurs 100,00.
Kapitalen udgør herefter kr. 125.000,00.
Stiftelsesdato:
01.08.1985
Seneste vedtægtsdato:
01.08.1985
Kapital:
kr. 80.000,00
Indbetalingsmåde:
kontant/i værdier kr. 80.000,00 til kurs 100,0
Direktion:
Direktør, cand.pharm Jørgen da Mouskis Reumert, 2820 Gentofte
Selskabet tegnes af en direktør alene
Revision:
Statsaut. revisor Erik Munk, 4000 Roskilde
Første regnskabsår:
01.08.1985 - 31.12.1986
Regnskabsår:
01.01 - 31.12
P-number 1002564559Nygade 6, 1164 København K
No other current company drawn.